Brain-specific inhibition of mTORC1 eliminates side effects resulting from mTORC1 blockade in the periphery and reduces alcohol intake in mice

Yann Ehinger; Ziyang Zhang; Khanhky Phamluong; Drishti Soneja; Kevan M. Shokat; Dorit Ron

doi:10.1038/s41467-021-24567-x

Nature Communications (Jul 2021)

Brain-specific inhibition of mTORC1 eliminates side effects resulting from mTORC1 blockade in the periphery and reduces alcohol intake in mice

Yann Ehinger,
Ziyang Zhang,
Khanhky Phamluong,
Drishti Soneja,
Kevan M. Shokat,
Dorit Ron

Affiliations

Yann Ehinger: Department of Neurology, University of California San Francisco
Ziyang Zhang: Department of Cellular and Molecular Pharmacology and Howard Hughes Medical Institute, University of California
Khanhky Phamluong: Department of Neurology, University of California San Francisco
Drishti Soneja: Department of Neurology, University of California San Francisco
Kevan M. Shokat: Department of Cellular and Molecular Pharmacology and Howard Hughes Medical Institute, University of California
Dorit Ron: Department of Neurology, University of California San Francisco

DOI: https://doi.org/10.1038/s41467-021-24567-x
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 11

Abstract

Read online

Chronic use of mTORC1 inhibitors produces undesirable side effects in humans which limit their value for CNS disorders treatment. The authors present a binary drug strategy to protects mTORC1 activity in the periphery and show its potential utility in preclinical models of alcohol use disorder.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal